← All trials
NCT02425904
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2015
- Primary completion
- Jan 1, 2019
- Completion date
- Sep 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 85
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- St. Baldrick's FoundationCollaborator
- Cookies for Kids' CancerCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- SanofiCollaborator
- North American Consortium for HistiocytosisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.